Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2002

Open Access 01-12-2002 | Research article

Anti-HIV-1 activity of cellulose acetate phthalate: Synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles

Authors: A Robert Neurath, Nathan Strick, Shibo Jiang, Yun-Yao Li, Asim K Debnath

Published in: BMC Infectious Diseases | Issue 1/2002

Login to get access

Abstract

Background

Cellulose acetate phthalate (CAP), a promising candidate microbicide for prevention of sexual transmission of the human immunodeficiency virus type 1 (HIV-1) and other sexually transmitted disease (STD) pathogens, was shown to inactivate HIV-1 and to block the coreceptor binding site on the virus envelope glycoprotein gp120. It did not interfere with virus binding to CD4. Since CD4 is the primary cellular receptor for HIV-1, it was of interest to study CAP binding to HIV-1 complexes with soluble CD4 (sCD4) and its consequences, including changes in the conformation of the envelope glycoprotein gp41 within virus particles.

Methods

Enzyme-linked immunosorbent assays (ELISA) were used to study CAP binding to HIV-1-sCD4 complexes and to detect gp41 six-helix bundles accessible on virus particles using antibodies specific for the α-helical core domain of gp41.

Results

1) Pretreatment of HIV-1 with sCD4 augments subsequent binding of CAP; 2) there is synergism between CAP and sCD4 for inhibition of HIV-1 infection; 3) treatment of HIV-1 with CAP induced the formation of gp41 six-helix bundles.

Conclusions

CAP and sCD4 bind to distinct sites on HIV-1 IIIB and BaL virions and their simultaneous binding has profound effects on virus structure and infectivity. The formation of gp41 six-helical bundles, induced by CAP, is known to render the virus incompetent for fusion with target cells thus preventing infection.
Appendix
Available only for authorised users
Literature
1.
Neurath AR, Strick N, Li Y-Y, Lin K, Jiang S: Design of a "microbicide" for prevention of sexually transmitted diseases using "inactive" pharmaceutical excipients. Biologicals. 1999, 27: 11-21. 10.1006/biol.1998.0169.CrossRefPubMed
2.
Gyotoku T, Aurelian L, Neurath AR: Cellulose acetate phthalate (CAP): an 'inactive' pharmaceutical excipient with antiviral activity in the mouse model of genital herpesvirus infection. Antiviral Chem Chemother. 1999, 10: 327-332.CrossRef
3.
Neurath AR, Li Y-Y, Mandeville R, Richard L: In vitro activity of a cellulose acetate phthalate topical cream against organisms associated with bacterial vaginosis. J Antimicrob Chemother. 2000, 45: 713-714. 10.1093/jac/45.5.713.CrossRefPubMed
4.
Neurath AR: Microbicide for prevention of sexually transmitted diseases using a pharmaceutical excipient. AIDS Patient Care STDS. 2000, 14: 215-219. 10.1089/108729100317830.CrossRefPubMed
5.
Neurath AR, Stick N, Li Y-Y, Radigan L, Jiang S: A microbicide for the third millenium (cellulose acetate phthalate). XIII International AIDS Conference. 2000, 713-717.
6.
Manson KH, Wyand MS, Miller C, Neurath AR: The effect of a cellulose acetate phthalate topical cream on vaginal transmission of simian immunodeficiency virus in rhesus monkeys. Antimicrob Agents Chemother. 2000, 44: 3199-3202. 10.1128/AAC.44.11.3199-3202.2000.CrossRefPubMedPubMedCentral
7.
Kawamura T, Cohen SS, Borris DL, Aquilino EA, Glushakova S, Margolis LB, Orenstein JM, Offord RE, Neurath AR, Blauvelt A: Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med. 2000, 192: 1491-1500. 10.1084/jem.192.10.1491.CrossRefPubMedPubMedCentral
8.
Neurath AR, Strick N, Li YY, Debnath AK: Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect Dis. 2001, 1: 17-10.1186/1471-2334-1-17.CrossRefPubMedPubMedCentral
9.
Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, et al: Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996, 381: 661-666. 10.1038/381661a0.CrossRefPubMed
10.
Orloff SL, Kennedy MS, Belperron AA, Maddon PJ, McDougal JS: Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. J Virol. 1993, 67: 1461-1471.PubMedPubMedCentral
11.
Johnson VA, Barlow MA, Chou TC, Fisher RA, Walker BD, Hirsch MS, Schooley RT: Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by recombinant soluble CD4 and 3'-azido-3'-deoxythymidine. J Infect Dis. 1989, 159: 837-844.CrossRefPubMed
12.
Pan X-Z, Qiu Z-D, Baron PA, Gold JWM, Polsky B, Chou T-C, Armstrong D: Three-drug synergistic inhibition of HIV-1 replication in vitro by 3'-fluoro-3'-deoxythymidine, recombinant soluble CD4, and recombinant interferon-alpha. AIDS Res Hum Retroviruses. 1992, 8: 589-595.CrossRefPubMed
13.
Sattentau QJ, Moore JP: Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med. 1991, 174: 407-415. 10.1084/jem.174.2.407.CrossRefPubMed
14.
Gorny MK, Zolla-Pazner S: Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J Virol. 2000, 74: 6186-6192. 10.1128/JVI.74.13.6186-6192.2000.CrossRefPubMedPubMedCentral
15.
Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 1998, 393: 705-711. 10.1038/31514.CrossRefPubMed
16.
Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998, 393: 648-659. 10.1038/31405.CrossRefPubMed
17.
Wyatt R, Sodroski J: The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 1998, 280: 1884-1888. 10.1126/science.280.5371.1884.CrossRefPubMed
18.
Jones PL, Korte T, Blumenthal R: Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors. J Biol Chem. 1998, 273: 404-409. 10.1074/jbc.273.1.404.CrossRefPubMed
19.
Dimitrov AS, Xiao X, Dimitrov DS, Blumenthal R: Early intermediates in HIV-1 envelope glycoprotein-mediated fusion triggered by CD4 and co-receptor complexes. J Biol Chem. 2001, 276: 30335-30341. 10.1074/jbc.M103788200.CrossRefPubMed
20.
Jiang S, Lin K, Lu M: A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol. 1998, 72: 10213-10217.PubMedPubMedCentral
21.
Jiang S, Lin K, Zhang L, Debnath AK: A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J Virol Methods. 1999, 80: 85-96. 10.1016/S0166-0934(99)00041-5.CrossRefPubMed
22.
Neurath AR, Strick N, Li Y-Y, Jiang S: Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins. AIDS Res Hum Retroviruses. 1993, 9: 1195-1208.CrossRefPubMed
23.
Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M: The role of mononuclear phagocytes in HTLV-III/LAV infection. Science. 1986, 233: 215-219.CrossRefPubMed
24.
Neurath AR, Debnath AK, Strick N, Li Y-Y, Lin K, Jiang S: Blocking of CD4 cell receptors for the human immunodeficiency virus type 1 (HIV-1) by chemically modified bovine milk proteins: potential for AIDS prophylaxis. J Mol Recognition. 1995, 8: 304-316.CrossRef
25.
Farzan M, Vasilieva N, Schnitzler CE, Chung S, Robinson J, Gerard NP, Gerard C, Choe H, Sodroski J: A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. J Biol Chem. 2000, 275: 33516-33521. 10.1074/jbc.M007228200.CrossRefPubMed
26.
Lusso P, Cocchi F, Balotta C, Markham PD, Louie A, Farci P, Pal R, Gallo RC, Reitz MS: Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): Failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol. 1995, 69: 3712-3720.PubMedPubMedCentral
27.
Chou T-C, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984, 22: 27-55. 10.1016/0065-2571(84)90007-4.CrossRefPubMed
28.
Willey RL, Theodore TS, Martin MA: Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope. J Virol. 1994, 68: 4409-4419.PubMedPubMedCentral
29.
Quanta 2000. 9685 Scranton Road, San Diego, CA. 92121, Accelrys, Inc.
30.
Hart TN, Ness SR, Read RJ: Critical evaluation of the research docking program for the CASP2 challenge. Proteins. 1997, Suppl 1: 205-209. 10.1002/(SICI)1097-0134(1997)1+<205::AID-PROT27>3.3.CO;2-P.CrossRefPubMed
31.
Nicholls A, Sharp KA, Honig B: Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins: Structure, Function, and Genetics. 1991, 11: 281-296.CrossRef
32.
Moebius U: Cluster report: CD4. In Leucocyte Typing IV: White Cell Differentiation Antigens. Edited by: Knapp W, Dörken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGKr. 1989, Oxford, Oxford University Press, 314-316.
33.
Parker CE, Deterding LJ, Hager-Braun C, Binley JM, Schulke N, Katinger H, Moore JP, Tomer KB: Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol. 2001, 75: 10906-10911. 10.1128/JVI.75.22.10906-10911.2001.CrossRefPubMedPubMedCentral
34.
Sattentau QJ, Moore JP, Vignaux F, Traincard F, Poignard P: Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J Virol. 1993, 67: 7383-7393.PubMedPubMedCentral
35.
Sattentau QJ, Zolla-Pazner S, Poignard P: Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virol. 1995, 206: 713-717.CrossRef
36.
Layne SP, Merges MJ, Dembo M, Spouge JL, Conley SR, Moore JP, Raina JL, Renz H, Gelderblom HR, Nara PL: Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virol. 1992, 189: 695-714. 10.1016/0042-6822(92)90593-E.CrossRef
37.
McKeating JA, McKnight A, Moore JP: Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: Effects on infectivity and neutralization. J Virol. 1991, 65: 852-860.PubMedPubMedCentral
38.
Littman DR: Chemokine receptors: keys to AIDS pathogenesis?. Cell. 1998, 93: 677-680. 10.1016/S0092-8674(00)81429-4.CrossRefPubMed
39.
Neurath AR, Strick N, Jiang S: Synthetic peptides and anti-peptide antibodies as probes to study interdomain interactions involved in virus assembly: The envelope of the human immunodeficiency virus (HIV-1). Virol. 1992, 188: 1-13. 10.1016/0042-6822(92)90729-9.CrossRef
40.
Weber T, Zemelman BV, McNew JA, Westermann B, Gmachl M, Parlati F, Sollner TH, Rothman JE: SNAREpins: minimal machinery for membrane fusion. Cell. 1998, 92: 759-772. 10.1016/S0092-8674(00)81404-X.CrossRefPubMed
41.
Munoz-Barroso I, Durell S, Sakaguchi K, Appella E, Blumenthal R: Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol. 1998, 140: 315-323. 10.1083/jcb.140.2.315.CrossRefPubMedPubMedCentral
42.
Furuta RA, Wild CT, Weng Y, Weiss CD: Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol. 1998, 5: 276-279. 10.1038/871.CrossRefPubMed
43.
de Rosny E, Vassell R, Wingfield PT, Wild CT, Weiss CD: Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptor-activated conformations of the envelope glycoprotein. J Virol. 2001, 75: 8859-8863. 10.1128/JVI.75.18.8859-8863.2001.CrossRefPubMedPubMedCentral
44.
Thali M, Furman C, Helseth E, Repke H, Sodroski J: Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glcoprotein and subsequent membrane fusion events. J Virol. 1992, 66: 5516-5524.PubMedPubMedCentral
45.
Gallo SA, Puri A, Blumenthal R: HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 env-mediated fusion process. Biochemistry. 2001, 40: 12231-12236. 10.1021/bi0155596.CrossRefPubMed
46.
Kliger Y, Shai Y: Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J Mol Biol. 2000, 295: 163-168. 10.1006/jmbi.1999.3368.CrossRefPubMed
47.
Chan DC, Kim PS: HIV entry and its inhibition. Cell. 1998, 93: 681-684. 10.1016/S0092-8674(00)81430-0.CrossRefPubMed
48.
Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature. 1997, 387: 426-430. 10.1038/387426a0.CrossRefPubMed
49.
Tan K, Liu J, Wang J, Shen S, Lu M: Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A. 1997, 94: 12303-12308. 10.1073/pnas.94.23.12303.CrossRefPubMedPubMedCentral
50.
Chan DC, Fass D, Berger JM, Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997, 89: 263-273. 10.1016/S0092-8674(00)80205-6.CrossRefPubMed
51.
Lu M, Ji H, Shen S: Subdomain folding and biological activity of the core structure from human immunodeficiency virus type 1 gp41: implications for viral membrane fusion. J Virol. 1999, 73: 4433-4438.PubMedPubMedCentral
52.
Weissenhorn W, Wharton SA, Calder LJ, Earl PL, Moss B, Aliprandis E, Skehel JJ, Wiley DC: The ectodomain of HIV-1 env subunit gp41 forms a soluble, α-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J. 1996, 15: 1507-1514.PubMedPubMedCentral
53.
LeDuc DL, Shin YK: Insights into a structure-based mechanism of viral membrane fusion. Biosci Rep. 2000, 20: 557-570. 10.1023/A:1010463005396.CrossRefPubMed
54.
55.
Chen CH, Greenberg ML, Bolognesi DP, Matthews TJ: Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41. AIDS Res Hum Retroviruses. 2000, 16: 2037-2041. 10.1089/088922200750054765.CrossRefPubMed
56.
Cormier EG, Persuh M, Thompson DAD, Lin SW, Sakmar TP, Olson WC, Dragic T: Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc Natl Acad Sci U S A. 2000, 97: 5762-5767. 10.1073/pnas.97.11.5762.CrossRefPubMedPubMedCentral
57.
Cormier EG, Tran DN, Yukhayeva L, Olson WC, Dragic T: Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J Virol. 2001, 75: 5541-5549. 10.1128/JVI.75.12.5541-5549.2001.CrossRefPubMedPubMedCentral
58.
Carr CM, Kim PS: A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell. 1993, 73: 823-832. 10.1016/0092-8674(93)90260-W.CrossRefPubMed
59.
Carr CM, Chaudhry C, Kim PS: Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc Natl Acad Sci U S A. 1997, 94: 14306-14313. 10.1073/pnas.94.26.14306.CrossRefPubMedPubMedCentral
60.
Melikyan GB, Markosyan RM, Hemmati H, Delmedico MK, Lambert DM, Cohen FS: Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol. 2000, 151: 413-423. 10.1083/jcb.151.2.413.CrossRefPubMedPubMedCentral
61.
Chen J, Wharton SA, Weissenhorn W, Calder LJ, Hughson FM, Skehel JJ, Wiley DC: A soluble domain of the membrane-anchoring chain of influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low-pH-induced conformation. Proc Natl Acad Sci U S A. 1995, 92: 12205-12209.CrossRefPubMedPubMedCentral
62.
Korte T, Ludwig K, Booy FP, Blumenthal R, Herrmann A: Conformational intermediates and fusion activity of influenza virus hemagglutinin. J Virol. 1999, 73: 4567-4574.PubMedPubMedCentral
63.
64.
Skehel JJ, Wiley DC: Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem. 2000, 69: 531-569. 10.1146/annurev.biochem.69.1.531.CrossRefPubMed
Metadata
Title
Anti-HIV-1 activity of cellulose acetate phthalate: Synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles
Authors
A Robert Neurath
Nathan Strick
Shibo Jiang
Yun-Yao Li
Asim K Debnath
Publication date
01-12-2002
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2002
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-2-6

Other articles of this Issue 1/2002

BMC Infectious Diseases 1/2002 Go to the issue

Research article

A short purification process for quantitative isolation of PrPScfrom naturally occurring and experimental transmissible spongiform encephalopathies

Research article

Shorter courses of parenteral antibiotic therapy do not appear to influence response rates for children with acute hematogenous osteomyelitis: a systematic review

Research article

Smoking, season, and detection of chlamydia pneumoniaeDNA in clinically stable COPD patients

Research article

Kinetics of maternal immunity against rabies in fox cubs (Vulpes vulpes)

Research article

Prevalence and risk factors for vaginal Candidacolonization in women with type 1 and type 2 diabetes

Research article

Stable hepatitis C virus RNA detection by RT-PCR during four days storage
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits